Business
Vicore Announces Presentations at the 2025 American Thoracic Society International Conference
STOCKHOLM, SE / ACCESS Newswire / April 23, 2025 / Vicore Pharma Holding (STO:VICO) Stockholm, April 23, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ...
About this update from Vicore Pharma Holding Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / April 23, 2025 / Vicore Pharma Holding (STO:VICO)","length":83,"tagName":"p"},{"type":"text","content":"Stockholm, April 23, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the Company will present multiple oral presentations and posters at the 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16 - May 21, 2025.","length":392,"tagName":"p"},{"type":"text","content":"These posters and presentations will highlight new translational data demonstrating buloxibutid's unique upstream mechanism of action for the treatment of idiopathic pulmonary fibrosis (IPF), a further analysis of buloxibutid's Phase 2a data in IPF patients reflecting disease-modifying potential, and the patient-centric approaches that Vicore has taken in both the ongoing Phase 2b ASPIRE study in IPF patients and in digital health innovation.","length":454,"tagName":"p"},{"type":"text","content":"Oral PresentationsA Digital Psychological Therapy Improves Health-related Quality of Life in Pulmonary Fibrosis Patients Using Antifibrotic TreatmentMini Symposium A14: Advances in the Diagnosis and Management of ILDDate: Sunday, May 18, 2025Presentation Time: 10:03 AM PTLocation: Room 25, Hall E (North Building, Exhibition Level), Moscone Center","length":353,"tagName":"p"},{"type":"text","content":"The AIR Phase 2 Trial of the Angiotensin II Type 2 Receptor Agonist, Buloxibutid, in Individuals With Idiopathic Pulmonary Fibrosis: A Responder AnalysisMini Symposium D98: Tracing the Scar in Interstitial Lung DiseasesDate: Wednesday, May 21, 2025Presentation Time: 12:24 PM PTLocation: Room 3006/3008 (West Building, Level 3), Moscone Center","length":347,"tagName":"p"},{"type":"text","content":"Poster PresentationsASPIRE Trial in Idiopathic Pulmonary Fibrosis: A Patient Experience-focused Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Trial of the Novel Angiotensin II Type 2 Receptor Agonist BuloxibutidThematic Poster Session A74: Fibrotic Lung Disease RevisitedDate: Sunday, May 18, 2025Presentation Time: 11:30 AM PTLocation: Area G, Hall F (North Building, Exhibition Level), Moscone Center","length":428,"tagName":"p"},{"type":"text","co...